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Abstract
Mitogen-activated protein kinase (MAPK) pathways mediate some important cellular processes and are likely to also regulate
preimplantation development. The role of p38 MAP kinase signaling during murine preimplantation development was investigated in the
present study. p38 MAPK, p38-regulated or -activated kinase (PRAK; MK5), map kinase-activated protein kinase 2 (MK2), and heat shock
protein 25 (hsp25) mRNAs and proteins were detected throughout preimplantation development. Two-cell stage embryos cultured in the
presence of SB220025 and SB203580 (specific inhibitors of p38 MAPK a/h), progressed to the eight-cell stage with the same frequency as
controls; however, treated embryos halted their development at the 8- to 16-cell stage. In addition, embryos treated with p38 MAPK
inhibitors displayed a complete loss of MK2 and hsp25 phosphorylation and also a complete loss of filamentous actin as indicated by the
absence of rhodamine–phalloidin staining. In these inhibitor-treated groups, the embryos were composed of a mixture of compacting and
noncompacting cells, and the embryos were one to two cell divisions behind controls. Treated embryos remained viable as the developmental
blockade was rescued by removing embryos from the drug treatment and placing them in drug-free medium until they progressed to the
blastocyst stage. This study demonstrates that p38 MAPK activity is required to support development through the murine preimplantation
interval.
D 2004 Elsevier Inc. All rights reserved.
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Introduction
Preimplantation development is critical to the establish-
ment of a viable mammalian pregnancy. It is estimated that
only 40% of human embryos successfully implant to estab-
lish a pregnancy (Edwards, 1997). Despite a reasonably
sound understanding of the specific events associated with
preimplantation development, including zygotic genome
activation (Memili et al., 1998; Schultz, 1993; Zimmermann
and Schultz, 1994), the onset of compaction (Collins and
Fleming, 1995; Fleming et al., 2000; Sutherland and Cal-
arco-Gillam, 1983), and blastocyst formation (Betts et al.,
1998; Watson and Barcroft, 2001; Watson et al., 1990,
1992b), comparatively little is known about the intracellular
signaling pathways that must regulate these events.
To identify specific signaling molecules, which may play
a role in the progression of the preimplantation embryo, we
used differential display-reverse transcription polymerase
chain reaction (DD-RT-PCR). From this screen, we identi-
fied, among others (Natale and Watson, 2002; Natale et al.,
2000, 2001), the cDNA for p38-regulated or -activated
kinase (PRAK), a downstream effector of the p38 mito-
gen-activated protein kinase (MAPK) subfamily.
MAPK pathways mediate some cellular processes, in-
cluding cell proliferation, growth, differentiation, and death
(reviewed by Ono and Han, 2000). The p38 MAPK family
consists of four isoforms, p38 MAPK a, h, g, and y, which
share more than 60% amino acid identity. The p38 MAPK
cascade is activated in response to many types of stress and
proinflammatory cytokines. In addition, p38 MAPK iso-
forms act through multiple effectors (reviewed by Kyriakis
and Avruch, 2001; Ono and Han, 2000), including several
transcription factors as well as MAP kinase-activated
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protein kinase-2 (MK2; Huot et al., 1997) and/or PRAK
(New et al., 1998), which is also designated as MK5 (Ni et
al., 1998). PRAK and MK2 are specifically activated by
active p38 MAPK a and/or h. These proteins in turn
phosphorylate a member of the small heat shock protein
family (hsp), hsp25/27 (Davidson and Morange, 2000; New
et al., 1998).
Targeted inactivation of the p38 MAPK a gene resulted
in embryonic lethality at or around E10.5 (Adams et al.,
2000; Allen et al., 2000; Mudgett et al., 2000; Yang et al.,
2000). p38 MAPK a, like an upstream regulator of the
p38 cascade, Mekk3, is essential for placental morpho-
genesis (Adams et al., 2000; Allen et al., 2000; Mudgett et
al., 2000; Yang et al., 2000). Although the p38a/
mutant mouse proceeds through the preimplantation peri-
od, the expression of PRAK during this interval led us to
hypothesize that p38a and other members of the p38
MAPK family are required to direct the developmental
program that oversees preimplantation development. We
have predicted that multiple p38 MAPK family members
might be expressed during the preimplantation period,
permitting the p38a/ mutant mouse embryos to survive
this early developmental interval. Thus, the primary ob-
jective of the present study was to investigate the expres-
sion profiles and function of components of the p38
MAPK signaling pathway in murine preimplantation de-
velopment in vitro.
Our results demonstrate that all members of this MAPK
pathway are expressed during murine preimplantation de-
velopment. More importantly, inhibition of p38 MAPK
activity (using cytokine suppressive anti-inflammatory
drugs, CSAIDs, pharmacological inhibitors of p38 MAPK
a/h; Cirillo et al., 2002; Davidson and Morange, 2000; Huot
et al., 1997; Zayzafoon et al., 2002) results in a reversible
arrest of preimplantation development, suggesting that p38
MAPK a/h activity is required for successful preimplanta-
tion development to occur.
Materials and methods
Superovulation and mouse embryo collection
Female CD-1 mice (Charles River, Wilmington, MA,
USA), 3–4 weeks of age, were injected with 5 IU pregnant
mare serum gonadotrophin (PMSG; Sigma, St. Louis, MO,
USA) followed by 5 IU human chorionic gonadotrophin
(hCG; Sigma) 48 h later and mated with CB6F1/J males
(Charles River). Successful mating was determined the next
morning (which was considered to be day 1 of develop-
ment) by the presence of a vaginal plug. Embryos were
collected at specified times following hCG injection, which
correspond to appropriate cleavage stages: mature, unfertil-
ized eggs, 18-h post-hCG; two-cell, 48 h; four-cell, 60 h;
eight-cell, 65–68 h; morulae, 80–85 h; and blastocyst, 90 h.
Zygotes through to the eight-cell stage were flushed from
oviducts of female mice using flushing medium I (calcium
lactate, 1.71 mM; sodium pyruvate, 0.25 mM; bovine serum
albumin, 3 mg/ml; and 10 Leibovitz-modified Hank’s
balanced salt solution all diluted with water to 1) (Spindle,
1980). Morulae and blastocysts were flushed from uteri on
day 4 using flushing medium II (CaCl2, 1.8 mM; amino
acids: 0.1 mM L-arginine, 0.5 mM L-cysteine, 1.03 mM L-
histidine, 0.2 mM L-isoleucine, 1 mM L-leucine, 2 mM L-
lysine, 0.25 mM L-methionine, 0.5 mM L-phenylalanine, 2
mM L-threonine, 0.1 mM L-tryptophan, 0.1 mM L-tyrosine,
1 mM L-valine, 2 mM L-glutamine, and 1 BME vitamins
added to 10 Leibovitz-modified HBSS diluted with water
to 1) (Spindle, 1980).
RNA extraction and reverse transcription
Total RNA was extracted from frozen pools of preim-
plantation embryos using the RNeasy total RNA extraction
kit (QIAGEN, Mississauga, ON, Canada) and the manu-
facturer’s suggested protocol, followed by vacuum drying
to reduce the volume for reverse transcription (RT). As
previously described (Barcroft et al., 1998; Offenberg et
al., 2000), RT reactions were performed using oligo-dT
(Gibco BRL). Samples were incubated for 90 min at 42jC
in a total volume of 20 Al consisting of 50 mM Tris–HCl
(pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5
mM dNTPs, and 200 units of Superscript II (Gibco BRL).
Reactions were terminated by heating the samples to 95jC
for 5 min.
PCR amplification
Polymerase chain reaction (PCR) was conducted as
previously described (Barcroft et al., 1998; Offenberg et
al., 2000), using a total amount of cDNA equal to two
embryos of each stage per reaction. Briefly, PCR reactions
were carried out in a volume of 50 Al consisting of 0.2 U of
AmpliTaq Gold (Perkin Elmer, PE Applied Biosystems,
Mississauga, ON, Canada), 1 PCR Gold Buffer (PE
Applied Biosystems), 1.5–2.0 mM MgCl2, 0.2 mM of each
dNTP, and 1.0 AM of each PCR primer using a Perkin Elmer
GeneAmp 2400 thermal cycler. AmpliTaq Gold was acti-
vated by an initial incubation at 95jC for 10 min followed
by 40 cycles of amplification: 95jC for 30 s, 52–56jC for
60 s, 72jC for 30 s, with a final extension of 10 min at
72jC. PCR products were then resolved on 2.0% agarose
gels containing 0.5 Ag/ml ethidium bromide (Sigma). PCR
reactions were repeated a minimum of three times using
cDNA prepared from embryos at each of the indicated
stages and isolated from three developmental series.
PCR primers
Gene-specific primers for PCR were designed and syn-
thesized (Gibco BRL) for p38 MAPK a, h, g, and y,
PRAK, MK2, and hsp25 based on available human and
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mouse full-length and EST nucleotide sequences in Gen-
Bank nucleotide databases. PCR primer sets were designed
to regions of nucleotides conserved across species. The
primer pairs used to amplify p38 a, h, g, and y, MK2, and
hsp25 are reported in Table 1. In addition, primer sets
designed to bracket an intron of the h-actin gene (Watson
et al., 1992a) were used to assess the efficiency of the RNA
extraction or reverse transcription and to ensure the absence
of DNA contamination in each sample before investigation
of expression of the target genes. Positive (tissue cDNA;
heart, liver, and kidney) and negative control (no cDNA
template) samples were included for each primer set in each
experiment.
Cloning and sequencing of RT-PCR products
RT-PCR products amplified from embryonic cDNAwere
selected for each target gene and purified using a QIAquick
Gel Extraction Kit (QIAGEN). Purified cDNA was then
cloned by TA cloning protocol into pGEM-T (Promega,
Madison, WI, USA). Several clones representing each
amplicon were chosen and submitted for nucleotide se-
quencing (DNA Sequencing Facility, Robarts Research
Institute, London, ON, Canada). To confirm identity of
each PCR product, an NCBI BLAST search was then
carried out on each nucleotide sequence to compare it to
sequences available in the GenBank nucleotide sequence
databases.
Whole-mount indirect immunofluorescence and actin
labeling
Characterization and localization of expression of mem-
bers of the p38 MAPK signaling pathway at the protein
level in preimplantation stage mouse embryos were
assessed by whole-mount indirect immunofluorescence
and detected by laser scanning confocal microscopy as
previously described (Barcroft et al., 1998). Briefly, preim-
plantation embryo series, including two-cell, four-cell,
eight-cell (compacting stages), morula, and blastocyst
stages, were examined. Immunofluorescence experiments
were repeated on a minimum of three distinct developmen-
tal series, containing at least five embryos representative of
each developmental stage for each protein. To assess
background and nonspecific binding of secondary antibody,
embryos were exposed to the same procedure in the absence
of primary antibody.
The following commercial antibodies were used: p38
MAPK and MAPKAP K5 (both are mouse monoclonal
antisera raised against human protein; BD Transduction
Laboratories); MK2, phospho-MK2, and phospho-hsp25
(all are rabbit anti-human polyclonal antisera; Cell Signaling
Technologies); PRAK (goat anti-human polyclonal antise-
rum; Santa Cruz Biotechnology, sheep anti-human poly-
clonal; Upstate Biotechnology); and hsp25 (goat anti-human
polyclonal antiserum; Santa Cruz Biotechnology). We tested
all primary antibodies over a range of dilutions and found
that all were most effective at a dilution of 1:100 from the
commercial stock concentration. In addition, the specificity
of each antiserum was verified by conducting a series of
Western immunoblots applied to a selection of murine
Table 1
Nucleotide sequences for polymerase chain reaction amplification of p38
MAPK a, h, g, y, MK2, PRAK (MK5), and hsp25 (shown in the 5V–
3Vdirection)
Gene product Primer Primer sequence Size (bp)
P38 MAPK a 5V AGGCCATGGTGCATGTGTGT 320
3V AGTAGCTGGAGGAGGAGGAG
P38 MAPK h 5V GGCTGCATCATGGCTGAACT 544
3V TGAGAGGCGCTTCTTGAGGA
P38 MAPK g 5V TCTCAGCTTCAAGCCTCCTA 402
3V TCCTAAGCTCTGCTCACTCT
P38 MAPK y 5V GTCTGTTGGTTGCATCATGG 630
3V GGATCTCTTGAGTTGCAGGT
MK 2 5V AACGCCATCACCGACGACTAC 537
3V CAGGACTTCCGGAGCCACATA
PRAK 5V TGGCCAACATGAGAATCCAGG 330
3V TGAATCCACGACCATTCCAGC
hsp25 5V CTCTTCGATCAAGCTTTCGG 410
3V CTCAGGGGATAGGGAAGAGG
Shown also is the size in base pairs (bp) of the expected amplicon.
Fig. 1. Detection of transcripts encoding p38 MAPK isoforms and pathway
constituents during murine preimplantation development. RT-PCR products
encoding p38 MAPKa (A), 320 bp; h (B), 544 bp; g (C), 402 bp; y (D),
630 bp; and MK2 (E), 537 bp. PRAK (F), 330 bp, and hsp25 (G), 410 bp,
were detected throughout preimplantation development. O, ovulated
oocytes; 2, 4, 8, M, and B represent two-, four-, eight-, morula, and
blastocyst stage embryos, respectively. () indicates no-RT negative
control, while (+) indicates tissue RT positive control.
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tissues and by immunofluorescence using mouse embryonic
fibroblast cells (data not shown).
For whole-mount indirect immunofluorescence, embryos
were washed two times in phosphate-buffered saline (PBS)
and then fixed in 2% paraformaldehyde in PBS for 20 min
at room temperature. Following fixation, embryos were
washed in PBS and either processed immediately for im-
munofluorescence or stored at 4jC in PBS + 0.09% sodium
azide for up to 3 weeks. For immunofluorescence staining,
fixed embryos were permeabilized and blocked concurrently
by incubation at room temperature in PBS + 5% donkey
serum + 0.01% Triton X-100 for 1 h. Embryos were then
washed in PBS and incubated at room temperature for 1 h in
PBS + 1% Donkey Serum + 0.005% Triton X-100 and the
primary antibody (1:100). This was followed by rigorously
washing the embryos at 37jC with PBS, which was
Fig. 2. Distribution of p38 MAPK pathway constituent proteins during murine preimplantation development. In all micrographs, green indicates positive
staining for the respective primary antibody, red indicates F-actin (rhodamine–phalloidin), and blue indicates nuclei (DAPI). Phosphorylated p38 MAPK
(A, two-cell; B, eight-cell; and C, blastocyst) and PRAK (MK5) (D, two-cell; E, eight-cell; and F, blastocyst) were detected in the cytoplasm of blastomeres
throughout development. Phosphorylated MK2 (G, two-cell; H, eight-cell; I, blastocyst; and J, blastocyst-P-MK2 only) was detected primarily in the
nucleus of blastomeres throughout development. In cells undergoing mitosis, MK2 was detected throughout the cytoplasm. Phosphorylated hsp25 (K, eight-
cell; L, morula; and M, blastocyst) was detected in the cytoplasm and in association with some nuclei of blastomeres at all stages of development. Bottom
panels (-‘ve) show negative controls and are representative of embryos that have been exposed to FITC-conjugated secondary only (no primary antibody) in
addition to rhodamine–phalloidin and DAPI. Scale bar = 25 Am.
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changed frequently over 1 h. The washed embryos were
incubated at room temperature in PBS + 1% donkey serum
+ 0.005% Triton X-100 and FITC-conjugated secondary
antibodies (Jackson Immuno Labs, MA, USA; 1:200 dilu-
tion). Embryos were washed rigorously once again as
described above and mounted in Antifade Mounting
Reagent (BioRad, Mississauga, ON, Canada). To visualize
F-actin localization and stain DNA within nuclei, the first
wash following secondary antibody included TRITC-conju-
gated Phallodin (F-actin-Phalloidin-Tetramethylrhodamine
B isothiocyanate, Sigma-Aldrich; diluted 1:200 from 5 Ag/
ml stock solution) and DAPI (nuclei-4V, 6-diamidino-2-
phenylindole dihydrochloride; Sigma-Aldrich; diluted
1:2000 from 1 mg/ml stock solution). Immunofluorescence
patterns were visualized by microscopy using a Zeiss
compound microscope (Zeiss Axiovert; Carl Zeiss Inc.,
Thornwood, NY, USA) equipped with epifluorescent optics
and confocal laser-scanning microscopy (Zeiss LSM 410
and computer system equipped with Zeiss LSM software;
Carl Zeiss Inc.).
p38 MAPK inhibition experiments
Murine embryos were flushed from oviducts of timed-
pregnant mice at the two-cell stage (48 h post-hCG; as
described above), pooled, washed, and divided into one of
five KSOMaa (Ho et al., 1995) microdrop culture treat-
ments: (1) KSOMaa alone, (2) KSOMaa + 20 AM
SB202474 (inactive analogue), (3) KSOMaa + 0.2 AM
SB220025, (4) KSOMaa + 2.0 AM SB220025, and (5)
KSOMaa + 20 AM SB220025. This experiment was also
duplicated using a second inhibitor, SB203580, in place of
SB220025. This class of compounds has been determined
to specifically inhibit both p38 MAPK a and h at the
concentrations used in this study (Cirillo et al., 2002;
Davidson and Morange, 2000; Huot et al., 1997; Zayzafoon
et al., 2002). Embryos were assessed for morphology and
progression through cleavage divisions at 24 h postdrug
treatment (72 h post-hCG), at which point half of the
embryos in groups 3, 4, and 5 were removed from culture,
washed, and placed in fresh KSOMaa culture drops for the
remainder of the experiment. All embryos were then
assessed at 48 h postdrug treatment (96 h post-hCG) to
measure development to the blastocyst stage. Cell viability
was determined at this time by assaying for uptake of a vital
dye (trypan blue; Humason, 1979). Embryos from each
treatment group were fixed as described above for whole-
mount indirect immunofluorescence and stained with DAPI
to count embryo cell numbers.
Statistical analysis
Statistical analysis of data was carried out using Sigma-
Stat (Jandel Scientific, San Rafael, CA) software package.
Data showed normal distribution and one-way ANOVAwas
used to determine treatment effects followed by Tukey’s
multiple comparison test to determine statistical signifi-
cance. Differences of P V 0.05 were considered significant.
Results
Detection of mRNAs encoding p38 MAPK signaling
pathway constituents in the preimplantation embryo
The application of RT-PCR methods to preimplantation
embryo cDNA samples resulted in the detection of mRNAs
Fig. 3. The effect of treatment with SB220025 on preimplantation
development. Two-cell stage murine embryos were treated in culture with
0 AM (control); 20 AM inactive analogue SB202474 (inactive); and 0.2,
2.0, and 20 AM SB220025. (A) Following 24 h of treatment with 20 AM
SB220025, there was a significant reduction in the proportion of embryos
undergoing compaction. a and b indicate significant differences between
compacted embryo frequencies; c and d indicate significant differences
between eight-cell embryo frequencies ( P V 0.05). (B) Following 48 h of
treatment with 2.0 and 20 AM SB220025, there was a significant
reduction in the proportion of embryos that developed to the blastocyst
stage. a, b, and c indicate significant differences between blastocyst
frequencies; d and e indicate significant differences between morula
frequencies; f and g indicate significant differences between compacted
embryo frequencies ( P V 0.05).
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encoding all four p38 MAPK isoforms (a, h, g, and y),
PRAK (MK5), MK2, and hsp25 throughout murine preim-
plantation development. The expected size amplicons for
each of p38 MAPK a, h, g, and y, PRAK, MK2, and hsp25
were detectable at each stage of the developmental series
examined (oocyte, two-cell, four-cell, eight-cell, morula, and
blastocyst; Table 1, Fig. 1). In all cases, the sequence of each
product was identical to known murine cDNA sequences.
Distribution of p38 MAPK signaling pathway proteins in the
preimplantation embryo
We next used antisera raised against p38 MAPK
pathway constituents to determine the presence and local-
ization of these proteins throughout preimplantation devel-
opment by immunofluorescence. First, antisera specific for
both phosphorylated p38 MAPK (Figs. 2A–C) and total
p38 MAPK (data not shown) were used. p38 MAPK
protein was detectable in the cytoplasm of blastomeres at
all stages of preimplantation development, and this pattern
consisted of both diffuse cytoplasmic staining combined
with a more intense vesicular localization pattern. The
distribution of phospho-p38 MAPK a/h immunofluores-
cence completely mirrored the distribution of total p38
MAPK a/h protein in all embryo stages. Similarly, PRAK
protein was detectable at all stages of preimplantation
development (Figs. 2D–F) with fluorescent foci observed
in each blastomere in a diffuse cytoplasmic staining
pattern in all embryos.
In contrast, at all stages of preimplantation development
investigated, MK2 (data not shown) and phosphorylated-
MK2 immunofluorescence were concentrated primarily in
the nucleus of each blastomere (Figs. 2G–J). Interestingly,
in mitotic blastomeres (observed by DNA staining with
DAPI), MK2 and phosphorylated-MK2 immunofluores-
cence were dispersed throughout the dividing cell and
consisted of a punctate distribution throughout the cyto-
plasm (for example, see Figs. 2H and I). This pattern of
immunofluorescence staining was unique to MK2.
Fig. 4. The effect of 48 h of treatment with SB203580 on preimplantation
development. Two-cell stage murine embryos were treated in culture with 0
AM (control); 20 AM inactive analogue SB202474 (inactive); and 0.2, 2.0,
and 20 AM SB203580. Following 48 h of treatment with 20 AM SB203580,
there was a significant reduction in the proportion of embryos that
developed to the blastocyst stage. a and b indicate significant differences
between blastocyst frequencies ( P V 0.05).
Fig. 5. Morphology of murine embryos treated with p38 MAPK a/h inhibitors. Two-cell murine embryos cultured in the absence of inhibitor (control; A) and
20 AM SB202474 (inactive analogue; B) progressed normally to the compacted eight-cell stage following 24 h in culture. Embryos treated with 20 AM
SB220025 (C) were predominantly uncompacted following 24 h of treatment. Two-cell murine embryos cultured for 48 h in the absence of inhibitor (control; D)
and 20 AM SB202474 (inactive analogue; E) progressed normally to the blastocyst stage. Embryos cultured in 20 AM SB220025 (F) did not develop to the
blastocyst stage.
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The hsp25 and phosphorylated-hsp25 were also detected
throughout murine preimplantation development (Figs. 2K–
M). At all developmental stages, embryos exhibited both a
cytoplasmic and nuclear localization pattern for hsp25
immunofluorescence. The phosphorylated form of hsp25
had a similar cellular distribution; however, the cytoplasmic
localization changed from a largely punctate pattern ob-
served mostly in early cleavage stages (i.e., four- and eight-
cell stages) to that of a more generalized even cytoplasmic
distribution by the morula and blastocyst stages. This
transition in hsp25-staining pattern may be indicative of a
transition from polymeric to dimeric hsp, which occurs as
hsp25 phosphorylation increases in other cell types (Butt et
al., 2001).
Inhibition of the p38 MAPK signaling pathway
Having ascertained that all members of the p38 MAPK
family were present in the preimplantation embryo, we next
sought to determine whether blocking p38 MAPK activity
would disrupt preimplantation development. To investigate
this possibility, embryos were incubated for specific inter-
vals in one of five treatment groups: (1) KSOMaa alone, (2)
KSOMaa + 20 AM SB202474 (inactive analogue), (3)
KSOMaa + 0.2 AM SB220025, (4) KSOMaa + 2.0 AM
SB220025, and (5) KSOMaa + 20 AM SB220025. This
experiment was then repeated using SB203580.
Treatment of two-cell stage embryos with a 20-AM
concentration of the p38 MAPK a/h inhibitor SB220025
for 24 h resulted in a significant (P V 0.05) reduction in the
proportion of eight-cell compacted embryos, as compared to
that observed for other treatment concentration groups and
untreated controls (Fig. 3A). Treated embryos continued to
cleave from the two-cell stage to the eight-cell stage in the
presence of the inhibitors (0.2, 2.0, and 20 AM); however,
there was a delay in their progression to the 16-cell stage in
the 20-AM SB220025 treatment group (Figs. 5A–C). Em-
bryos treated with SB203580 displayed a similar trend
following 24 h of treatment; however, the proportion of
compacted eight-cell embryos was not reduced significantly
in the SB203580 treatment groups (data not shown).
Following 48 h of culture, the frequency of development
of embryos to the blastocyst stage did not vary significantly
between those groups treated with 0.2 AM SB220025 or
Fig. 6. Effect of p38 MAPK inhibition on the phosphorylation of MK2 and hsp25. In all micrographs, green indicates positive staining for the respective
primary antibody and blue indicates nuclei (DAPI). Murine embryos cultured in the presence of 2 or 20 AM SB220025 for 24 h did not display any
fluorescence following application of whole-mount immunofluorescence assays to detect phosphorylated forms of MK2 (top row) and hsp25 (middle row).
Embryos cultured in the absence of the inhibitor (control) or with 20 AM SB202474 (inactive analogue; data not shown) displayed the expected fluorescence
patterns for both MK2 and hsp25. In the lower panel, fluorescence was detected using antisera recognizing both phosphorylated and nonphosphorylated forms
of hsp25 (hsp25) and MK2 (MK2) in embryos cultured in the presence of 20 AM SB220025 for 24 h. Scale bar = 25 Am.
D.R. Natale et al. / Developmental Biology 268 (2004) 76–8882
SB203580, 2.0 AM SB203580 or 20 AM SB202474 (inac-
tive analogue), and untreated controls. In contrast, a signif-
icant proportion (P V 0.05) of two-cell stage embryos
treated with 2.0 AM SB220025, 20 AM SB203580, and 20
AM SB220025 failed to develop to the blastocyst stage
(Figs. 3B and 4). Embryos treated with 20 AM SB220025
reached an early stage of compaction as indicated by the
appearance of increased interblastomeric contact; however,
only one such treated embryo was observed to develop a
fluid-filled cavity (Figs. 5D–F).
Cell counts on treated embryos stained with DAPI
indicated that 50% (13 of 26 examined) of the embryos in
the 20-AM SB220025 treatment groups were blocked at the
16-cell stage, whereas approximately 42% (11 of 26 exam-
ined) were blocked at the eight-cell stage. The remaining
embryos (8% of the total) contained fewer than eight cells.
In contrast, at the same time points, the majority of embryos
in control groups (KSOMaa + vehicle and 20 AM
SB202474) progressed to the 32-cell stage or beyond (24/
30, 80%, and 23/30, 77%, respectively).
Embryo viability was assessed for each control and
treatment group immediately following the 48-h interval
by assaying for the uptake of the vital dye trypan blue.
Baseline dye uptake was observed in blastomeres of one to
two embryos in each group including controls. We did not
observe any increase in dye uptake (indicative of loss of cell
integrity and thus viability) from controls in embryos
exposed to either 20 AM of the inhibitors, SB203580,
SB220025, or 20 AM of the inactive analogue, SB202474
(example, Figs. 8B and i).
Effect of p38 MAPK inhibitors on phosphorylation of MK2
and hsp25
To assess the ability of SB220025 and SB203580 to
effectively and specifically inhibit p38 MAPK activity, we
investigated the phosphorylation state of the downstream
substrates, MK2 and hsp25. Following treatment with
SB220025 and SB203580 for 24 h, embryos in all of the
treatment groups including controls were assessed by
whole-mount indirect immunofluorescence techniques using
antisera specific to the total and phosphorylated forms of
MK2 and hsp25. Embryos from the control groups dis-
played fluorescence patterns corresponding to those already
described for phospho-MK2 and phospho-hsp25 (Fig. 6). In
embryos treated at the 20-AM concentrations with either
SB220025 (Fig. 6) or SB203580 (data not shown), fluores-
cence was undetectable using either anti-phospho-MK2 or
Fig. 7. Effect of p38 MAPK inhibitors on embryonic F-actin. Murine embryos assessed for filamentous actin by rhodamine–phalloidin fluorescence displayed
an actin network typical of the 8- to 16-cell stage in the control group (A) and the group treated with 20 AM SB202474 (B). Embryos cultured for 24 h in the
presence of 20 AM SB220025 displayed a loss of filamentous actin as indicated by the absence of rhodamine–phalloidin fluorescence (C). Following removal
from SB220025 treatment, however, embryos resumed development and displayed a restored filamentous actin network (D). Scale bar = 15 Am.
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anti-phospho-hsp25 antisera. Treatments with 2 AM
SB220025 (Fig. 6) also resulted in a complete loss of
anti-phospho-MK2 or anti-phospho-hsp25 fluorescence,
while treatment with 2 AM SB203580 resulted in a marked
reduction in anti-phospho-MK2 or anti-phospho-hsp25 fluo-
rescence (data not shown). In embryos treated with either
SB220025 or SB203580, expression of nonphosphorylated
MK2 and hsp25 was still detectable (Fig. 6, lower panel).
These data collectively demonstrate that p38 MAPK activity
was suppressed in treated embryos.
Effect of p38 MAPK inhibitors on embryonic actin
Since p38 MAPK is an important regulator of filamen-
tous actin in many cell types, we investigated the affect of
treatment with p38 MAPK inhibitors on the structure of
embryonic filamentous actin (Davidson and Morange, 2000;
Huot et al., 1997). Treatment with a 20-AM concentration of
the p38 MAPK a/h inhibitor SB220025 for 24 h resulted in
a complete loss of filamentous actin in blocked 8- to 16-cell
embryos as indicated by the loss of rhodamine–phalloidin
fluorescence (Fig. 7C). Control embryos and embryos
treated with SB202474 displayed the expected filamentous
actin network that is typical of 8- to 16-cell stage embryos
(Figs. 7A and B, respectively). Embryos treated with 2.0
AM SB220025 displayed an obvious reduction in rhoda-
mine–phalloidin fluorescence but never displayed a com-
plete loss of fluorescence (data not shown). Embryos
released from p38 MAPK inhibitors resumed development
as described below and also displayed a return of rhoda-
mine–phalloidin fluorescence and a restoration of the fila-
mentous actin network (Fig. 7D). Our results indicate that
p38 MAPK is a potent regulator of filamentous actin in the
preimplantation embryo.
Rescue of embryos exposed to the p38 MAPK a/b-specific
inhibitors SB220025 and SB203580
We next sought to determine whether the effects of the p38
MAPK a/h-specific inhibitors, SB220025 and SB203580,
were reversible. To this end, embryos were incubated in one
of the five media treatments for 24 h and then washed with
normal KSOMaa and maintained in this medium for an
additional 24–48 h. All embryos removed from SB203580
following treatment for 24 h resumed development to the
blastocyst stage with the same frequency as controls. A
significant number of embryos removed from SB220025-
containing media (2.0 and 20 AM SB220025; PV 0.05) after
24 h of treatment failed to progress to the blastocyst stage at
the same time as embryos in untreated controls and 20 AM
inactive analogue, SB202474, treatment groups (Fig. 8A).
Despite removal from the inhibitor and placement in fresh
Fig. 8. Recovery of preimplantation embryos from 24 h of treatment with SB220025. Murine embryos undergoing treatment with SB220025 from the two-cell
stage were removed from treatment following 24 h, washed, and placed in fresh culture drops in the absence of SB220025. Results indicate that embryos
cultured initially in the presence of 2.0 and 20 AM SB220025 fail to recover completely from p38 inhibition in only 24 h. (A) There is a significant reduction in
blastocyst formation in these groups (a, b, and c indicate significant differences between blastocyst formation frequencies; d, e, and f indicate significant
differences between morula frequencies; g and h indicate significant differences between compacted embryo frequencies; P V 0.05). (B) Morphology of
embryos treated with SB220025 for 48 h; (i) morphology of embryos removed from SB220025 treatment at 24 h and cultured for an additional 24 in drug-free
medium; (ii) and morphology of embryos removed from SB220025 treatment at 24 h and cultured for an additional 48 h in drug-free medium (iii).
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KSOMaa medium for 24 h, these embryos did not appear to
be any further advanced than embryos continuously cultured
in SB220025 for the entire 48 h (Fig. 8B and ii). However, in
contrast to embryos exposed for 48 h to the inhibitor, those
treated for only 24 h and then removed to regular media
displayed a higher proportion of 16 cell or greater embryos in
their group (9/26 20–24 cells, 35%; 12/26 16 cells, 46%; and
5/26 8 cells, 19%), suggesting that release from the inhibitor
and progression towards the blastocyst stage had been
initiated. To determine whether SB220025-treated embryos
recovered completely, we extended the culture period in
drug-free KSOMaa medium for an additional 24 h (72 h total
culture time from the two-cell stage). Embryos so treated
progressed to the blastocyst stage, including blastocoele
formation accompanied by cell proliferation (>30 cells, 28/
34, 82%; 16–24 cells, 3/34, 9%; and <16 cells, 9%), in a
similar frequency to controls after 48 h of culture (28/34,
82%; Fig. 8B and iii). Therefore, none of treatments resulted
in a permanent blockade of development. Embryos treated
with 20 AM SB220025 simply required an additional 24 h to
recover and resume their development to the blastocyst stage
following treatment.
Discussion
This is the first study to investigate p38 MAPK signaling
during murine preimplantation development. From our
results, we can conclude that p38 MAPK signaling is
required to promote development through to the blastocyst
stage. We have previously applied differential display-re-
verse transcription polymerase chain reaction (DD-RT-PCR)
to provide a global assessment of gene expression patterns
throughout preimplantation development (Natale et al.,
2000, 2001). From this analysis, we identified PRAK
(MK5) mRNA expression during preimplantation develop-
ment. Application of gene-specific RT-PCR methods in the
present study indicated that mRNA encoding PRAK (MK5)
and other members of the p38 MAPK signaling cascade,
including p38 a, h, g, y, and the specific downstream
effectors, MK2 and hsp25, are expressed throughout murine
preimplantation development.
The p38 MAPK signaling cascade regulates a variety of
cellular activities in different cell and tissue types including
the cell cycle, apoptosis, and cellular differentiation, all of
which must be tightly controlled in mammalian preimplan-
tation development (Bavister, 1987; Niemann and Wren-
zycki, 2000; Watson et al., 1992b). This signaling pathway
is influenced by a variety of stimuli including growth
factors, cytokines, and pathogens. Most notably, and of
relevance to our study, p38 MAPK signals through PRAK
(MK5) in response to environmental stress (New et al.,
1998; Ono and Han, 2000). Changes in osmolarity, temper-
ature, oxygen tension, and oxygen radical metabolites
activate p38 MAPK a/h (reviewed by Ono and Han,
2000). Osmolarity and oxygen tension are crucial variables
in embryo culture and must be tightly regulated to promote
optimal frequencies of development to the blastocyst stage
(Baltz, 2001; Bernardi et al., 1996; Byatt-Smith et al., 1991;
Hashimoto et al., 2000; Quinn and Harlow, 1978; Wren-
zycki et al., 2001). The p38 MAPK signaling system may
serve an important role in mediating and transmitting signals
from the environment (in vivo and in vitro) that assist in
coordinating embryonic development.
Our protein localization studies indicate that p38 MAPK,
PRAK (MK5), MK2, and hsp25 are present in mouse
embryos throughout preimplantation development. In addi-
tion, our results indicate that each of these proteins is
phosphorylated and likely active throughout murine preim-
plantation development.
PRAK (MK5) shares sequence homology with MK2, is
activated by similar upstream activators, and shares down-
stream targets (Ni et al., 1998). However, our findings
suggest that each protein exhibits distinct subcellular dis-
tributions in early mouse embryos. PRAK (MK5) was
found in the cytoplasm of blastomeres at all developmental
stages, whereas MK2 was primarily associated with the
nucleus except in dividing blastomeres wherein it is
located throughout the cell. Both PRAK and MK2 phos-
phorylate and activate hsp25 in response to p38 MAPK
activity (New et al., 1998; Stokoe et al., 1992); however, it
is likely that based on their subcellular distribution in
preimplantation embryos, they have additional and inde-
pendent functions.
Our experiments examining the consequences of p38
MAPK inhibition indicate that p38 MAPK activity is
required for murine blastocyst development in vitro. A
significant proportion of two-cell embryos incubated with
either 2.0 or 20 AM SB220025 or 20 AM SB203580 failed
to progress to the blastocyst stage and halted their develop-
ment at the 8- to 16-cell stage. In addition, following 48 h of
SB220025 or SB203580 treatment, these embryos were one
to two cell cycles behind the control groups. Importantly,
embryo viability was not compromised by these treatments.
These data suggest that p38 MAPK activity is required
beginning at the eight-cell stage to promote development to
the blastocyst stage. This conclusion is further supported by
our inhibition-recovery data. In these experiments, embryos
recovered from inhibition and formed blastocysts at the
same frequency as observed in controls; however, this
recovery required an additional 24 h of culture (72 h of
total culture time versus 48 h).
Treatment with SB220025 had a more dramatic effect
than SB203580 on blastocyst development (2.0 and 20 AM
SB220025 versus 20 AM SB203580 following 48 h).
However, both compounds are specific inhibitors of p38
MAPK activity when used at the concentrations employed
in our study and in other studies SB220025 has been
demonstrated to be more potent (Wang et al., 1998). Active
p38 MAPK is required to phosphorylate MK2, which in
turn phosphorylates hsp25. In embryos treated with both
drugs, we observed an absence of phosphorylated forms of
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MK2 and hsp25. In embryos from the same treatment
groups, we observed no apparent affect to total MK2 and
hsp25 protein levels, demonstrating that p38 MAPK activity
is blocked by these treatments.
One of the most dramatic effects of treatment with p38
MAPK inhibitors that we observed was the complete loss of
filamentous actin in 8- to 16-cell-treated embryos. It is
possible that many of these observations on the effects of
p38 MAPK inhibition on preimplantation development
could be mediated via downstream effects to the actin
cytoskeleton. The adherens junction is dependent upon an
interaction of E-cadherin and catenins with the actin cyto-
skeleton (Pratt et al., 1982; Sutherland and Calarco-Gillam,
1983). The effects to development that we observed in the
presence of the inhibitor may reflect an impairment of
processes that regulate the establishment of stable cell-to-
cell adherens junctions in the 8- to 16-cell embryo during
compaction. We expect that inhibition of p38 MAPK by
CSAIDs prevents MK2 and/or PRAK phosphorylation of
hsp25 resulting in an abrupt impairment of actin polymer-
ization. Support for this hypothesis comes from studies that
have implicated hsp25/27 in mediating actin stabilization in
response to mitogens and stress (Benndorf et al., 1994; Butt
et al., 2001; Lavoie et al., 1993). Actin polymerization, as
measured by the presence of cortical F-actin, is decreased
when a mutant nonphosphorylated hsp27 is expressed
(Lavoie et al., 1993). When hsp27 is overexpressed, cortical
F-actin expression increases. In addition, mutation of serine
residues in hsp27 to mimic phosphorylation and activation
by MK2 results in increased actin polymerization (Butt et
al., 2001). Future studies will continue to investigate the
mechanism of p38 MAPK-controlled actin polymerization
in the preimplantation embryo.
Recently, p38 MAPK has been implicated as a regulator
of placental morphogenesis. Targeted inactivation of p38
MAPKa is accompanied by an early embryonic lethality in
mice and is associated with defects in placental develop-
ment (Adams et al., 2000; Allen et al., 2000; Mudgett et
al., 2000). Rescue experiments employing tetraploid wild-
type cells to form embryo aggregates (Guillemot et al.,
1994) with p38 MAPK a null embryos demonstrated that
normal placental and embryonic development occurs, im-
plying a trophoblast-specific phenotype for the p38
MAPKa knockout (Adams et al., 2000). Trophoblast cells
mediate attachment, invasion, and establish the embryonic
component of the placenta. These cells are derivatives of
the first differentiated cell type of the embryo, the trophec-
toderm. The trophectoderm develops from the totipotent
blastomeres of the eight-cell embryo. These studies define
a clear role for the p38 MAPK pathway during early
placentation, but they do not support our findings that
p38 MAPK activity is required to support preimplantation
development. This apparent variation in outcomes between
the two studies may be explained by our discovery that the
preimplantation murine embryo expresses multiple iso-
forms of p38 MAPK. The inhibitors we employed in the
present study target both p38 MAPK a and h activity (Fox
et al., 1998; Goedert et al., 1997; Lisnock et al., 1998;
Tong et al., 1997; Wilson et al., 1997). Therefore, we
contend that the exposure of all two-cell embryos to 20 AM
SB203580 or 20 AM SB220025, which will inhibit both
p38 MAPK a/h activity, precludes progression to the
blastocyst stage in vitro, whereas targeted inactivation of
p38 MAPK a alone does not. We propose that the dual
inactivation of p38 MAPK a and h will result in a
preimplantation lethal phenotype and a failure to support
development to the blastocyst stage in vivo.
The objectives of this work were to investigate the
expression and function of the p38 MAPK signaling path-
way through the preimplantation development interval. We
have shown mRNA expression and protein localization of
PRAK, p38 MAPK, MK2, and hsp25 throughout murine
preimplantation development. We have also demonstrated
that active p38 a/h MAPK signaling is required for devel-
opment from the 8- to 16-cell stage to the blastocyst stage
and that p38 MAPK is a regulator of filamentous actin
during preimplantation development.
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